These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 3214968

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency.
    Lacroix C, Tranvouez JL, Phan Hoang T, Duwoos H, Lafont O.
    Arzneimittelforschung; 1990 Jan; 40(1):76-9. PubMed ID: 2340003
    [Abstract] [Full Text] [Related]

  • 5. Changes in erythromycin pharmacokinetics induced by renal failure.
    Kanfer A, Stamatakis G, Torlotin JC, Fredj G, Kenouch S, Méry JP.
    Clin Nephrol; 1987 Mar; 27(3):147-50. PubMed ID: 3494560
    [Abstract] [Full Text] [Related]

  • 6. Haemodialysis of pyrazinamide in uraemic patients.
    Lacroix C, Hermelin A, Guiberteau R, Guyonnaud C, Nouveau J, Duwoos H, Lafont O.
    Eur J Clin Pharmacol; 1989 Mar; 37(3):309-11. PubMed ID: 2612545
    [Abstract] [Full Text] [Related]

  • 7. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH, van der Horst CM, Kaul S, Barbhaiya RH, Dukes GE.
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [Abstract] [Full Text] [Related]

  • 8. Profound mishandling of protein glycation degradation products in uremia and dialysis.
    Agalou S, Ahmed N, Babaei-Jadidi R, Dawnay A, Thornalley PJ.
    J Am Soc Nephrol; 2005 May; 16(5):1471-85. PubMed ID: 15800128
    [Abstract] [Full Text] [Related]

  • 9. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P, Tourkantonis A.
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [Abstract] [Full Text] [Related]

  • 10. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S, Orlando R, Bertoli M, Pegoraro P, Palatini P.
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
    Vanholder R, Camez A, Veys N, Van Loo A, Dhondt AM, Ringoir S.
    Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
    Teichert J, Tuemmers T, Achenbach H, Preiss C, Hermann R, Ruus P, Preiss R.
    J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
    [Abstract] [Full Text] [Related]

  • 13. [Simultaneous microdetermination of pyrazinamide and pyrazinoic acid by liquid chromatography].
    Lacroix C, Langlois B, Ménager S, Lafont O.
    Ann Biol Clin (Paris); 1987 Mar; 45(3):297-9. PubMed ID: 3662137
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oxalic Acid as a uremic toxin.
    Mydlík M, Derzsiová K.
    J Ren Nutr; 2008 Jan; 18(1):33-9. PubMed ID: 18089441
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.
    Lacroix C, Hoang TP, Nouveau J, Guyonnaud C, Laine G, Duwoos H, Lafont O.
    Eur J Clin Pharmacol; 1989 Jan; 36(4):395-400. PubMed ID: 2737233
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
    Eriksson T, Höglund P, Turesson I, Waage A, Don BR, Vu J, Scheffler M, Kaysen GA.
    J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM, Faull R, Fornasini G, Lemanowicz EF, Longo A, Pace S, Nation RL.
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Population Pharmacokinetic Modelling of Pyrazinamide and Pyrazinoic Acid in Patients with Multi-Drug Resistant Tuberculosis.
    Mugabo P, Mulubwa M.
    Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):519-530. PubMed ID: 30617957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.